Next 8th and 9th of February 2023 by Palazzo Trotti Mosti, Ferrara (Italy) the first Presto Cost action meeting. This meeting is based upon work from PRESTO COST Action CA21130, supported by COST (European Cooperation in Science and Technology).
| Name | Role |
|---|---|
| Elena ADINOLFI | Action Chair and Grant Holder Scientific Representative |
| Pablo PELEGRIN | Action Vice Chair |
| Alison GARTLAND | Science Communication Coordinator and WG5 Leader |
| Mariusz WIECKOWSKI | Grant Awarding Coordinator |
| Friedrich KOCH-NOLTE | WG1 Leader |
| Beata SPERLAGH | WG2 Leader |
| Valérie VOURET-CRAVIARI | WG3 Leader |
| Luca ANTONIOLI | WG4 Leader |
| Ivana NOVAK | Training School Coordinator |
| Sirje RÜÜTEL BOUDINOT | STSM Coordinator |
| Luke TATTERSALL | Social Media Manager |
| Elena DE MARCHI | Grant Holder Manager |
| Nome |
|---|
| Elena ADINOLFI |
| Elena DE MARCHI |
| Francesco DI VIRGILIO |
| Anna PEGORARO |
| Valentina VULTAGGIO POMA |
| Mario TARANTINI |
| Time | Speaker | Topic |
|---|---|---|
| 9:00-9:15 | Elena Adinolfi (IT) |
Welcome address |
| 9:15-10:45 | – |
Session 1: Chairs Friedrich Koch-Nolte (DE), Sahil Adriouch (FR) |
| 9:15-9:30 | Dariusz Gorecki (UK) | P2X7 purinoceptor in the pathogenesis and treatment of muscular dystrophy |
| 9:30-9:45 | Samuel Fountain (UK) | Targeting P2X3 and P2X4 in the cardiovascular and respiratory systems |
| 9:45-10:00 | Gennady Yegutkin (FI) | ATP and adenosine metabolism in cancer and inflammation |
| 10:00-10:15 | Michele Zanoni (IT) | How P2X receptors have contributed to our knowledge of glioblastoma pathophysiology |
| 10:15-10:30 | Mehmet Ugur (TR) | A different look at the intracellular signalling mechanisms of P2X7 receptor |
| 10:30-10:45 | Maria Domercq (ES) | Role of Irf5-P2X4 signaling pathway in myelin metabolism and in regeneration in multiple sclerosis |
| 10:45-11:00 | – | Coffee Break |
| 11:00-13:00 | – |
Session 2: Chairs Francesco Di Virgilio (IT), Ivana Novak (DK) |
| 11:00-11:15 | Mariusz Wieckowski (PL) | Mitochondria and P2X7– in health and disease |
| 11:15-11:30 | Roberta Rizzo (IT) | Role of Herpesvirus proteins in the control of host immune response |
| 11:30-11:45 | Friedrich Koch-Nolte (DE) | Targeting the P2X7 ion channel with functional nanobodies |
| 11:45-12:00 | Anna Marei Mann (DE) | Modulating the function of P2X7-expressing cells with Adeno-associated viral vectors that display P2X7-specific nanobodies |
| 12:00-12:15 | Danijela Laketa (RS) | Defining purinome in neuroinflammation during the course of experimental autoimmune encephalomyeltis |
| 12:15-12:30 | Katarzyna Roszek (PL) | ATP-mediated signaling of mesenchymal stem cells and cancer cells – friend or foe? |
| 12:30-12:45 | Kübra Ustaömer (TR) | Physiatrist view of PRESTO |
| 12:45-13:00 | Ana Maria Sebastião (PT) | Neuromodulation by purines – from neurogenesis towards neuronal signalling and neuroprotection |
| 13:00-14:00 | – | Lunch |
| 14:00-15:15 | Chairs: Beata Sperlagh (HU), Cécile Delarasse (FR) |
Session 1: Chairs Beata Sperlagh (HU), Cécile Delarasse (FR) |
| 14:00-14:15 | Cécile Delarasse (FR) | Purinergic receptor P2X7 in animal models of neuroinflammation |
| 14:15-14:30 | Hana Zemkova (CZ) | Role of the first transmembrane domain in trafficking, sensitization and dye uptake function of rat P2X7 receptor |
| 14:30-14:45 | Tobias Engel (IE) | The ATP-gated P2X7 receptor as theranostic biomarker for epilepsy |
| 14:45-15:00 | Nadežda Nedeljković (RS) | Neurobiology Lab at Faculty of Biology University of Belgrade – Who we are, what we do and how we can contribute to PRESTO? |
| 15:00-15:15 | Shai Berlin (IL) | NMDARs— from structure function to novel therapeutics |
| 15:15-15:30 | – | Coffee Break |
| 15:30-17:15 | Chairs: Dariusz Gorecki (UK), Tobias Engel (IE) |
Session 2: Chairs Dariusz Gorecki (UK), Tobias Engel (IE) |
| 15:30-15:45 | Beata Sperlagh (HU) | P2X receptors in psychiatric disorders |
| 15:45-16:00 | Carlos Matute (ES) | Roles of P2X4 and P2X7 in demyelination and remyelination |
| 16:00-16:15 | Todor Dudev (BG) | Molecular modeling studies on the mechanism of lithium’s mode of action intrating bipolar disorder |
| 16:15-16:30 | Felipe Ortega (ES) | Live imaging of Neural Stem Cells to study the role of purinergic signalling in their lineage progression |
| 16:30-16:45 | Marija Adzic (RS) | Can Probenecid counter neuroinflammation? Drug repurposing in vitro study in rat culture astrocyte model |
| 16:45-17:00 | Jasmina Trojachanec Pavlovska (MK) | From substance to new drugs: development of new drugs – Introduction to clinical trials |
| 17:00-17:15 | Milorad Dragic (RS) | Cerebral Open-Flow Microperfusion – a novel in vivo technique for continuous measurement of substance transport across intact blood-brain barrier |
| 17:15-19:00 | – | MC meeting |
| 20:30 | – | SOCIAL DINNER at Cusina e Butega, Corso Porta Reno 28, Ferrara |
| Time | Speaker | Topic |
|---|---|---|
| 9:00-10:30 | – | Session 1: Valérie Vouret-Craviari (FR), Elena De Marchi (IT) |
| 9:00-9:15 | Juan José Martinez (ES) | P2X7 receptor as a diagnostic and pharmacological target for infections and metabolic diseases |
| 9:15-9:30 | Maria João Queiroz (PT) | Synthesis of heterocyclic compounds with biological properties |
| 9:30-9:45 | Constantinos Athanassopoulos (EL) | P2X receptors’ modulators: Are they promising for anticancer combination therapies? |
| 9:45-10:00 | Anna Pegoraro (IT) | P2X7 activation and release of vesicles from tumour cells affecting metastasis |
| 10:00-10:15 | Sahil Adriouch (FR) | AAV vectors coding for nanobody-based biologics targeting P2X7 and their evaluation in animal models of colitis, experimental encephalitis, or cancer |
| 10:15-10:30 | Ankita Agrawal (DK) | P2X Receptors, A Clinical Biochemistry approach |
| 10:30-10:45 | – | Coffee Break |
| 10:45-12:30 | – | Session 2: Juan José Martinez (ES), Elena Adinolfi (IT) |
| 10:45-11:00 | Valérie Vouret-Craviari (FR) | Activation of the eATP/P2RX7/NLRP3/IL18 axis to treat pulmonary diseases |
| 11:00-11:15 | Benedetta De Ponte Conti (CH) | P2X7R mediated regulation of gut microbiota in cancer |
| 11:15-11:30 | Luke Tattersall (UK) | The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties |
| 11:30-11:45 | Ruth Murrell-Lagnado (UK) | P2X4, lysosome function and drug discovery at other ion channel targets |
| 11:45-12:00 | Ivana Novak (DK) | ATP signaling in pancreatic cancer: the P2X7 receptor |
| 12:00-12:15 | Joel Arrais (PT) | Artificial Intelligence for the targeted generation of novel compounds |
| 12:15-12:30 | Ines Zidi (TN) | P2XR in inflammation and cancer |
| 12:30-13:30 | – | Lunch |
| 13:30-15:00 | – |
Session 1: Chairs Luca Antonioli (IT), Pablo Pelegrin (ES) |
| 13:30-13:45 | Mark Young (UK) | The molecular determinants of antagonist binding at P2X receptors |
| 13:45-14:00 | Annette Nicke (DE) | Biochemical and functional analysis of P2X7 receptor signaling |
| 14:00-14:15 | Christa Müller (DE) | Tools and Drugs for P2X Receptors |
| 14:15-14:30 | Diego Dal Ben (IT) | Molecular modeling tools for the design of novel P2X ligands |
| 14:30-14:45 | Vanessa D’Antongiovanni (IT) | Anti-inflammatory effects of novel P2X4 receptor antagonists, NC-2600 and NP-1815-PX, in a murine model of colitis |
| 14:45-15:00 | Eric Boué-Grabot (FR) | Unravelling cell-specific function of P2X4 receptors in the brain using novel transgenic knock-in mice |
| 15:00-15:15 | – | Coffee Break |
| 15:15-16:45 | – |
Session 2: Chairs Diego Dal Ben (IT), Niklas Rye Jørgensen (DK) |
| 15:15-15:30 | Pablo Pelegrin (ES) | Modulation of the NLRP3 inflammasome by P2X7 receptor, implications in inflammation |
| 15:30-15:45 | Petros Petrou (CY) | ER stress-induced glycogen metabolism during myogenesis and the link with P2X receptor signaling |
| 15:45-16:00 | Elisa Tinelli (IT) | Identification of CNS penetrant P2X7 blockers: from the HTS to a preclinical model |
| 16:00-16:15 | Sirje Rüütel Boudinot (EE) | Validation of anti P2X4 monoclonal |
| 16:15-16:30 | Relja Suručić (BA) | P2X receptors and cannabinoids’ pathophysiological intersections with possible therapeutic outcomes |
| 16:30-16:45 | Victoria Maneu (ES) | P2X receptors in retinal neurodegenerative diseases: a window to brain degenerative diseases |
| 16:45-17:00 | – | Concluding remarks |